FcγRIIB-Blocking Antibody Combination for FcγRIIB-Negative Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing treatments using FcγRIIB-expressing antibodies are ineffective in enhancing the therapeutic activity of tumor direct-targeting antibodies in FcγRIIB-negative cancers, such as most solid cancers, and current anti-FcγRIIB antibodies do not enhance the efficacy of anti-HER2 treatments in cancers with low HER2 expression.
Innovation Solution
Combining a first antibody that specifically binds FcγRIIB via its Fab region and lacks or has reduced Fc region binding with a second antibody that targets tumor cells via activating Fcγ receptors, enhancing FcγR-dependent immune effector cell-mediated killing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If FcγRIIB-expressing antibodies are used to treat FcγRIIB-negative cancers, then the therapeutic activity of tumor direct-targeting antibodies should be enhanced, but the treatment is ineffective in FcγRIIB-negative cancers such as most solid cancers
Solution Approach 1:
The patent applies local quality by creating antibodies with differentiated Fc region properties - specifically, FcγRIIB-blocking antibodies with Fc regions engineered for impaired FcγR-binding (e.g., IgG1 N297Q mutation). This localized modification of the Fc region allows the antibody to block FcγRIIB without engaging other Fcγ receptors, enabling effective treatment of FcγRIIB-negative cancers while maintaining selectivity
Solution Approach 2:
The patent utilizes parameter changes by modifying the Fc region binding characteristics through genetic engineering (N297Q mutation) to alter the antibody's interaction with Fcγ receptors. This parameter modification transforms the antibody from one that would normally engage multiple FcγRs to one that specifically blocks FcγRIIB, thereby extending therapeutic efficacy to FcγRIIB-negative cancer types
2Reliability
If FcγRIIB-blocking antibodies with wildtype IgG1 Fc-proficient in FcγR-binding function are used, then they show efficient deletion of FcγRIIB-expressing B cells, but it remains unclear whether they would have utility in enhancing therapeutic activity of tumor direct-targeting antibodies in FcγRIIB-negative cancers
Solution Approach 1:
The patent uses FcγRIIB-blocking antibodies as intermediaries that specifically block the inhibitory FcγRIIB receptor without engaging activating Fcγ receptors. This intermediary function allows the tumor direct-targeting antibodies to exert their full therapeutic effect in FcγRIIB-negative cancers by removing the only remaining inhibitory pathway, thereby clarifying and enabling their utility in these cancer types
3Reliability
If FcγRIIB-blocking antibodies with Fc engineered for impaired FcγR-binding are used, then they show similar ability to enhance rituximab-mediated B cell depletion, but the applicability to tumor direct-targeting antibodies in FcγRIIB-negative cancers was not demonstrated
Solution Approach 1:
The patent demonstrates universality by showing that FcγRIIB-blocking antibodies with impaired FcγR-binding (e.g., IgG1 N297Q) can enhance the therapeutic activity of multiple different tumor direct-targeting antibodies (anti-HER2, anti-EGFR) in FcγRIIB-negative cancers. This multi-functional capability extends the utility beyond rituximab boosting to a broad class of tumor-targeting therapies
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This combination improves therapeutic efficacy by maximizing FcγR-dependent tumor cell-killing in FcγRIIB-negative cancers, including those with low HER2 expression, by optimizing FcγR activation and reducing inhibitory signaling.
Implementation Method 1
an antibody molecule that specifically binds FcγRIIB via its Fab region
Implementation Method 2
an antibody molecule that specifically binds to a receptor present on a tumor cell, which second antibody molecule has an Fc region that binds to at least one activating Fcγ receptor
Implementation Method 3
enhancing FcγR-dependent immune effector cell-mediated killing
Data Source
AI summary
Described is the use of a first antibody molecule that specifically binds FcγRIIB via its Fab region, but lacks Fc region or has reduced binding to Fcγ receptors via its Fc region, for use in combination with a second antibody molecule that specifically binds to a receptor present on a tumor cell, which second antibody molecule has an Fc region that binds to at least one activating Fcγ receptor in the treatment of an FcγRIIB-negative cancer in a patient, as well as pharmaceutical compositions and kits including these two antibody molecules, and methods of treating cancer using these two antibodies.